Trial Profile

A Phase 2 Randomized, Open-Label, Parallel Group Study to Assess the Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Casirivimab/imdevimab (Primary) ; Casirivimab/imdevimab (Primary) ; Elasomeran (Primary)
Indications COVID 2019 infections
Focus Pharmacodynamics
Sponsors Regeneron Pharmaceuticals

01 Jan 2025 Results evaluating Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses published in The Lancet Infectious Diseases.
09 Jan 2023 Status changed from active, no longer recruiting to completed.
07 Feb 2022 Planned End Date changed from 22 Nov 2022 to 25 Nov 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com